Name: | Dihydroergotamine |
---|---|
PubChem Compound ID: | 10531 |
Description: | A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS. |
Molecular formula: | C33H37N5O5 |
Molecular weight: | 583.678 g/mol |
Synonyms: |
DHE; NINDS_000592; Dihidroergotamina [INN-Spanish]; KBio3_001429; SPBio_001235; KBio1_000592; Diidroergotamina [DCIT]; KBio2_006673; Spectrum4_000958; BRN 5720196.
show more » |
Name: | Dihydroergotamine |
---|---|
Name (isomeric): | DB00320 |
Drug Type: | small molecule |
Description: | A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS. |
Synonyms: |
Dihydroergotaminum [INN-Latin]; Dihydroergotamine mesylate; 9,10-dihydro-ergotamine; Dihydroergotamine monomethanesulfonate; Dihidroergotamina [INN-Spanish]; Dihydroergotamine methanesulfonate
|
Brand: | DHE-45, Angionorm, Diergo, Endophleban, Ergotonin, Dergotamine, Ikaran, D.H.E., Dihydergot, DET MS, Orstanorm, Agit, D.H.E. 45, Ergont, Tonopres, Morena, Verladyn, Migranal, Dirgotarl, Ergomimet |
Category: | Sympatholytics, Analgesics, Non-Narcotic, Vasoconstrictor Agents, Analgesics, Dopamine Agonists, Anti-migraine Agents |
CAS number: | 6190-39-2 |
Indication: | For the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. |
---|---|
Pharmacology: |
Dihydroergotamine is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. Dihydroergotamine binds with high affinity to 5-HT1Da and 5-HT1Db receptors. It also binds with high affinity to serotonin 5-HT1A, 5-HT2A, and 5-HT2C...
show more » |
Mechanism of Action: |
Two theories have been proposed to explain the efficacy of 5-HT1D receptor agonists in migraine: 1) activation of 5-HT1D receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache and 2) activation of 5-HT...
show more » |
Absorption: | Interpatient variable and may be dependent on the administration technique |
Protein binding: | 93% (to plasma proteins) |
Biotransformation: | Hepatic |
Route of elimination: | The major excretory route of dihydroergotamine is via the bile in the feces. Only 6%-7% of unchanged dihydroergotamine is excreted in the urine after intramuscular injection. |
Half Life: | 9 hours |
Clearance: | 1.5 L/min |
Toxicity: | Side effects include abdominal pain, abnormal speech, coma, confusion, convulsions, hallucinations, increase and/or decrease in blood pressure, nausea, numbness, tingling, pain, and a bluish color of your fingersand toes, slowed breathing, vomiting |
Affected organisms: | Humans and other mammals |
Drug interaction: |
|
---|